Mimedx (MDXG) Non-Current Assets (2010 - 2026)
Mimedx's (MDXG) quarterly Non-Current Assets came in at $68.4 million in Q1 2026, down 2.78% year-on-year from $70.3 million in Q1 2025, and up 4.86% quarter-over-quarter from $65.2 million in Q4 2025.
Mimedx (MDXG) Non-Current Assets (2010 - 2026) Analysis & Trends
Mimedx has disclosed Non-Current Assets across 17 years of filings, most recently posting $68.4 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $68.4 million, down 2.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $268.7 million (down 7.44% YoY), and the FY2025 annual result was $65.2 million, down 9.51% from the prior year.
- Non-Current Assets came in at $68.4 million for Q1 2026 at Mimedx, up from $65.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $82.8 million in Q1 2024 to a low of $34.5 million in Q3 2023.
- The 5-year median for Non-Current Assets is $65.2 million (2025), against an average of $57.2 million.
- Across the five-year window, Non-Current Assets jumped 127.19% in 2024 and retreated 15.12% in 2025, its largest moves.
- Mimedx's Non-Current Assets stood at $37.2 million in 2022, then surged by 100.86% to $74.8 million in 2023, then decreased by 3.69% to $72.0 million in 2024, then declined by 9.51% to $65.2 million in 2025, then advanced by 4.86% to $68.4 million in 2026.
- The last three Non-Current Assets figures came in at $68.4 million (Q1 2026), $65.2 million (Q4 2025), and $64.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Mimedx | 546.28 Mn | 386.51 Mn | 41.62 Mn | 68.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.35 Mn |
| Dec 31, 2025 | 65.18 Mn |
| Sep 30, 2025 | 64.89 Mn |
| Jun 30, 2025 | 70.23 Mn |
| Mar 31, 2025 | 70.31 Mn |
| Dec 31, 2024 | 72.03 Mn |
| Sep 30, 2024 | 71.75 Mn |
| Jun 30, 2024 | 76.17 Mn |
| Mar 31, 2024 | 82.83 Mn |
| Dec 31, 2023 | 74.79 Mn |
| Sep 30, 2023 | 34.52 Mn |
| Jun 30, 2023 | 35.16 Mn |
| Mar 31, 2023 | 36.46 Mn |
| Dec 31, 2022 | 37.23 Mn |
| Sep 30, 2022 | 36.76 Mn |
| Jun 30, 2022 | 37.66 Mn |
| Mar 31, 2022 | 38.54 Mn |
| Dec 31, 2021 | 39.41 Mn |
| Sep 30, 2021 | 38.62 Mn |
| Jun 30, 2021 | 39.46 Mn |